Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$44.62 - $62.75 $740,022 - $1.04 Million
-16,585 Reduced 44.95%
20,314 $954,000
Q2 2024

Aug 13, 2024

SELL
$51.17 - $68.18 $111,806 - $148,973
-2,185 Reduced 5.59%
36,899 $1.99 Million
Q1 2024

May 13, 2024

SELL
$60.67 - $89.12 $2.12 Million - $3.11 Million
-34,936 Reduced 47.2%
39,084 $2.66 Million
Q4 2023

Feb 09, 2024

BUY
$38.62 - $72.18 $2.13 Million - $3.99 Million
55,220 Added 293.72%
74,020 $4.63 Million
Q1 2023

May 12, 2023

BUY
$41.0 - $56.12 $770,800 - $1.06 Million
18,800 New
18,800 $850,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.